UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 36,151 Shares of Alignment Healthcare, Inc. (NASDAQ:ALHC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC - Free Report) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 263,203 shares of the company's stock after acquiring an additional 36,151 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.14% of Alignment Healthcare worth $2,961,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. RiverPark Advisors LLC bought a new stake in Alignment Healthcare in the 4th quarter worth approximately $106,000. Tower Research Capital LLC TRC grew its position in shares of Alignment Healthcare by 146.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company's stock valued at $119,000 after acquiring an additional 6,286 shares during the period. Aigen Investment Management LP bought a new stake in shares of Alignment Healthcare during the 4th quarter valued at $129,000. AlphaQuest LLC bought a new stake in shares of Alignment Healthcare during the 4th quarter valued at $132,000. Finally, Dark Forest Capital Management LP bought a new stake in shares of Alignment Healthcare during the 4th quarter valued at $150,000. Institutional investors own 86.19% of the company's stock.

Alignment Healthcare Price Performance

NASDAQ ALHC opened at $14.79 on Friday. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.60 and a current ratio of 1.60. The firm's 50 day moving average price is $16.75 and its 200-day moving average price is $14.78. Alignment Healthcare, Inc. has a 52-week low of $7.05 and a 52-week high of $21.06. The company has a market cap of $2.93 billion, a PE ratio of -19.21 and a beta of 1.22.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.07. The company had revenue of $926.93 million during the quarter, compared to the consensus estimate of $889.83 million. Alignment Healthcare had a negative net margin of 5.84% and a negative return on equity of 108.69%. Alignment Healthcare's revenue was up 47.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.25) earnings per share. Sell-side analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Atlantic (Aln Hlth) L. General sold 17,000,000 shares of the firm's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $15.28, for a total transaction of $259,760,000.00. Following the completion of the transaction, the director now owns 44,302,175 shares of the company's stock, valued at $676,937,234. This trade represents a 27.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Sebastian Burzacchi sold 6,694 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $16.40, for a total transaction of $109,781.60. Following the transaction, the chief operating officer now directly owns 250,378 shares of the company's stock, valued at approximately $4,106,199.20. This trade represents a 2.60% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,784,649 shares of company stock valued at $273,320,208. Insiders own 7.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Bank of America boosted their price objective on shares of Alignment Healthcare from $15.50 to $18.50 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Robert W. Baird boosted their price objective on shares of Alignment Healthcare from $17.00 to $22.00 and gave the company an "outperform" rating in a research report on Tuesday, April 15th. Barclays boosted their price objective on shares of Alignment Healthcare from $8.00 to $9.00 and gave the company an "underweight" rating in a research report on Friday, February 28th. Piper Sandler boosted their price objective on shares of Alignment Healthcare from $14.00 to $21.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Alignment Healthcare from $14.00 to $17.00 and gave the company a "neutral" rating in a research report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Alignment Healthcare has a consensus rating of "Moderate Buy" and an average price target of $17.17.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.

Want to see what other hedge funds are holding ALHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alignment Healthcare, Inc. (NASDAQ:ALHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.